tert-Butyl (2S)-amino-3-tert-butoxycarbonylaminopropionate hydrochloride | 197358-53-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-Butyl (2S)-amino-3-tert-butoxycarbonylaminopropionate hydrochloride
• 英文别名: tert-Butyl (S)-2-amino-3-tert-butoxycarbonylaminopropionate hydrochloride；tert-butyl (2S)-2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate;hydrochloride
• CAS: 197358-53-5
• 化学式: C₁₂H₂₄N₂O₄*ClH
• 分子量: 296.794
• InChiKey: RMMATBBIKAKDDP-QRPNPIFTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  90.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-Butyl (2S)-amino-3-tert-butoxycarbonylaminopropionate hydrochloride 、 1-金刚烷甲醇 在 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 为溶剂， 生成 tert-Butyl (S)-2-(1-adamantylmethyloxycarbonylamino)-3-tert-butoxycarbonylaminopropionate
  参考文献：
  名称：

  Heterocyclic compounds, their preparation and their use as leucocyte

  摘要：

  公式I的化合物，##STR1##其中B、E、W、Y、Z、R、R.sup.2、R.sup.2a、R.sup.2b、R.sup.3、g和h在规范中有所指示的含义。公式I的化合物是有价值的药用活性化合物，例如适用于炎症性疾病的治疗和预防，例如类风湿性关节炎或过敏性疾病。公式I的化合物是白细胞粘附和迁移的抑制剂和/或整合素群中属于VLA-4粘附受体的拮抗剂。它们通常适用于由于白细胞粘附和/或白细胞迁移的不良程度引起的疾病的治疗或预防，或与之相关的疾病，或者在其中基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用起作用。此外，本发明还涉及制备公式I的化合物的方法，它们在治疗和预防所述疾病状态中的使用以及含有公式I的药物制剂。

  公开号：

  US06034238A1
• 作为产物：
  描述：

  tert-Butyl (2S)-benzyloxycarbonylamino-3-tert-butoxycarbonylaminopropionate 在 palladium-carbon 作用下， 以 甲醇 为溶剂， 生成 tert-Butyl (2S)-amino-3-tert-butoxycarbonylaminopropionate hydrochloride
  参考文献：
  名称：

  Heterocyclic compounds, their preparation and their use as leucocyte

  摘要：

  公式I的化合物，##STR1##其中B、E、W、Y、Z、R、R.sup.2、R.sup.2a、R.sup.2b、R.sup.3、g和h在规范中有所指示的含义。公式I的化合物是有价值的药用活性化合物，例如适用于炎症性疾病的治疗和预防，例如类风湿性关节炎或过敏性疾病。公式I的化合物是白细胞粘附和迁移的抑制剂和/或整合素群中属于VLA-4粘附受体的拮抗剂。它们通常适用于由于白细胞粘附和/或白细胞迁移的不良程度引起的疾病的治疗或预防，或与之相关的疾病，或者在其中基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用起作用。此外，本发明还涉及制备公式I的化合物的方法，它们在治疗和预防所述疾病状态中的使用以及含有公式I的药物制剂。

  公开号：

  US06034238A1

文献信息

• Heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
  申请人：Hoechst Aktiengesellschaft AG

  公开号：US05998447A1

  公开（公告）日：1999-12-07

  Compounds of the formula I ##STR1## in which B, D, E, R, W, Y, Z, b, c, d, e, f, g and have the meanings indicated in the claims, are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention relates to the use of compounds of the formula I, and of pharmaceutical preparations which contain such compounds, for the treatment and prophylaxis of diseases which are caused by an un desired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell--cell or cell-matrix interactions play a part which are based on interactions of VLA-4 receptors with their ligands, for example of inflammatory processes, rheumatoid arthritis or allergic disorders, and it also relates to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases. It further relates to novel compounds of the formula I.

  式I的化合物##STR1##中，其中B、D、E、R、W、Y、Z、b、c、d、e、f、g具有索引中指示的含义，是白细胞粘附和迁移的抑制剂和/或属于整合素群的粘附受体VLA-4的拮抗剂。本发明涉及利用式I的化合物以及含有这种化合物的药物制剂，用于治疗和预防由于白细胞粘附和/或白细胞迁移不受欢迎的程度引起的疾病，或与之相关的疾病，或其中细胞-细胞或细胞-基质相互作用起作用，这些相互作用基于VLA-4受体与其配体的相互作用，例如炎症过程、类风湿关节炎或过敏性疾病，还涉及利用式I的化合物生产用于此类疾病的药物。此外，还涉及式I的新化合物。
• 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US06423712B1

  公开（公告）日：2002-07-23

  The present invention relates to imidazolidine compounds of the formula I, The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use in the therapy and prophylaxis of the disease states mentioned and pharmaceutical preparations which contain compounds of the formula I.

  本发明涉及式I的咪唑啉化合物，式I的化合物是有价值的药用活性化合物，例如，适用于治疗和预防炎症性疾病，例如类风湿关节炎，或过敏性疾病。式I的化合物是白细胞粘附和迁移的抑制剂和/或整合素群中属于粘附受体VLA-4的拮抗剂。它们通常适用于治疗或预防由白细胞粘附和/或白细胞迁移的不良程度引起的疾病，或与之相关的疾病，或者在其中基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用发挥作用。本发明还涉及制备式I化合物的方法，它们在治疗和预防上述疾病状态的使用以及含有式I化合物的制药制剂。
• Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：US20020119999A1

  公开（公告）日：2002-08-29

  The present invention relates to 5-membered ring heterocycles of the formula I, 1 in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments. The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.

  本发明涉及式I的5元环杂环，其中E，F，G，W，Y和Z具有专利权要求中给出的含义，以及它们的制备和用作药物的用途。这些新型化合物被用作Vitronectin受体拮抗剂和骨吸收抑制剂。
• Imidazolidine derivatives, their preparation, their use, and pharmaceutical preparations comprising them
  申请人：——

  公开号：US20030125565A1

  公开（公告）日：2003-07-03

  The present invention relates to novel imidazolidine derivatives of the formula I, 1 in which B, E, W, Z, R, R 0 , R 2 , R 3 , e and h have the meanings indicated in the application. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use in the therapy and prophylaxis of the disease states mentioned and pharmaceutical preparations which contain compounds of the formula I.

  本发明涉及公式I的新型咪唑啉衍生物，其中B、E、W、Z、R、R0、R2、R3、e和h在申请书中所示。公式I的化合物是有价值的药物活性化合物，适用于治疗和预防炎症性疾病，例如类风湿性关节炎或过敏性疾病。公式I的化合物是白细胞粘附和迁移的抑制剂和/或属于整合素组的粘附受体VLA-4的拮抗剂。它们通常适用于由白细胞粘附和/或白细胞迁移的不良程度引起或与之相关的疾病的治疗或预防，或者在其中基于VLA-4受体与其配体的相互作用的细胞-细胞或细胞-基质相互作用发挥作用。此外，本发明还涉及公式I化合物的制备方法，它们在上述疾病状态的治疗和预防中的应用以及含有公式I化合物的制药制剂。
• Inhibitors or bone reabsorption and antagonists of vitronectin receptors
  申请人：Hoechst Aktiengesellschaft

  公开号：US06218415B1

  公开（公告）日：2001-04-17

  Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors The present invention relates to 5-membered ring heterocycles of the formula I, in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments. The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.

  小说骨重吸收的新抑制剂和vitronectin受体拮抗剂 本发明涉及式I的5-成员环杂环，其中E，F，G，W，Y和Z具有专利要求中给出的含义，以及它们的制备和作为药物的用途。 这些新化合物用作vitronectin受体拮抗剂和骨重吸收的抑制剂。